Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Alcoholism 💬
1件: SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
2 Alcoholism 💬
1件: SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
3 Alcoholism 💬
1件: SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
4 Alzheimer disease 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
5 Amphetamine addiction 💬
1件: SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
6 Amphetamine addiction 💬
1件: SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
7 Amphetamine addiction 💬
1件: SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
8 Arachidonic acid metabolism 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
9 C-type lectin receptor signaling pathway 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
10 cGMP-PKG signaling pathway 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
11 cGMP-PKG signaling pathway 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine hydrochloride 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
12 Chemical carcinogenesis - DNA adducts 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
13 Cocaine addiction 💬
1件: SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
14 Cocaine addiction 💬
1件: SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
15 Cocaine addiction 💬
1件: SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
16 Dopaminergic synapse 💬
1件: SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
17 Dopaminergic synapse 💬
1件: SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
18 Dopaminergic synapse 💬
1件: SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
19 Efferocytosis 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
20 Hormone signaling 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
21 Hormone signaling 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine hydrochloride 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
22 Human cytomegalovirus infection 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
23 Human papillomavirus infection 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
24 IL-17 signaling pathway 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
25 Insulin secretion 💬
1件: SNAP25 💬 Botulinum toxin type A 💬 Botulinum toxin type A 14件:  2 ,  5 ,  6 ,  7 , 13, 15, 17, 47, 51, 70, 113, 149, 171, 226 💬
26 Insulin secretion 💬
1件: SNAP25 💬 Prabotulinumtoxin A 💬 Botulinum toxin type A 14件:  2 ,  5 ,  6 ,  7 , 13, 15, 17, 47, 51, 70, 113, 149, 171, 226 💬
27 Kaposi sarcoma-associated herpesvirus infection 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
28 Leishmaniasis 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
29 MicroRNAs in cancer 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
30 Neuroactive ligand signaling 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
31 Neuroactive ligand signaling 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine hydrochloride 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
32 Neuroactive ligand signaling 💬
2件: SLC6A2, SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
33 Neuroactive ligand signaling 💬
2件: SLC6A2, SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
34 Neuroactive ligand signaling 💬
2件: SLC6A2, SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
35 Neuroactive ligand-receptor interaction 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
36 Neuroactive ligand-receptor interaction 💬
3件: ADRA2A, ADRA2B, ADRA2C 💬 Dexmedetomidine hydrochloride 💬 Dexmedetomidine 15件:  2 ,  4 ,  6 , 21, 22, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬
37 NF-kappa B signaling pathway 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
38 Ovarian steroidogenesis 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
39 Oxytocin signaling pathway 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
40 Parkinson disease 💬
1件: SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
41 Parkinson disease 💬
1件: SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
42 Parkinson disease 💬
1件: SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
43 Pathways in cancer 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
44 Pathways of neurodegeneration - multiple diseases 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
45 Pathways of neurodegeneration - multiple diseases 💬
1件: SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
46 Pathways of neurodegeneration - multiple diseases 💬
1件: SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
47 Pathways of neurodegeneration - multiple diseases 💬
1件: SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
48 Regulation of lipolysis in adipocytes 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
49 Retrograde endocannabinoid signaling 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
50 Serotonergic synapse 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
51 Small cell lung cancer 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
52 Synaptic vesicle cycle 💬
2件: SLC6A2, SLC6A3 💬 Bupropion hydrochloride 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
53 Synaptic vesicle cycle 💬
2件: SLC6A2, SLC6A3 💬 Bupropion 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
54 Synaptic vesicle cycle 💬
2件: SLC6A2, SLC6A3 💬 Bupropion hydrobromide 💬 Bupropion 6件:  8 , 18, 21, 96, 97, 171 💬
55 Synaptic vesicle cycle 💬
1件: SNAP25 💬 Botulinum toxin type A 💬 Botulinum toxin type A 14件:  2 ,  5 ,  6 ,  7 , 13, 15, 17, 47, 51, 70, 113, 149, 171, 226 💬
56 Synaptic vesicle cycle 💬
1件: SNAP25 💬 Prabotulinumtoxin A 💬 Botulinum toxin type A 14件:  2 ,  5 ,  6 ,  7 , 13, 15, 17, 47, 51, 70, 113, 149, 171, 226 💬
57 TNF signaling pathway 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬
58 VEGF signaling pathway 💬
1件: PTGS2 💬 Celecoxib 💬 Celecoxib 14件:  2 ,  3 ,  6 , 13, 34, 46, 70, 89, 96, 97, 107, 161, 171, 271 💬